Register
Login:
Share:
Email Facebook Twitter




AVCT Share Chat - RSS Feed

Avacta Share Chat (AVCT)



Share Price: 1.245Bid: 1.23Ask: 1.26Change: -0.01 (-0.80%)Faller - Avacta
Spread: 0.03Spread as %: 2.44%Open: 1.255High: 1.255Low: 1.245Yesterday’s Close: 1.255


Share Discussion for Avacta (AVCT)


Thread ViewThread View
Please Login or Register to post messages
Posts per page:


sukithedog
Posts: 494
Off Topic
Opinion:No Opinion
Price:0.78
View Thread (2)
RE: Sale of Optim.
12 Feb '15
agree, 10p with 2 years
 
Wisheyedbortum
Posts: 483
Observation
Opinion:Strong Buy
Price:0.77
View Thread (2)
Sale of Optim.
12 Feb '15
The sale of Optim was on the cards when we visited the company some time ago, so no surprises there. It will however facilitate the acceleration of the commercialization of the Affirmers which is great news for us shareholders. Onwards and upwards.
Coffee73
Posts: 15
Off Topic
Opinion:No Opinion
Price:0.77
Affirmers
9 Feb '15
Seems to be a head of steam building around the Affirmers with a few ties ups announced over the last few months. Shows that other pharma companies think the Affirmers have promise. Just need to see this translate into revenue. Fingers crossed.
Wisheyedbortum
Posts: 483
Answer
Opinion:Buy
Price:0.77
Suki.
9 Feb '15
Point taken. 125 mil traded altogether, don't remember ever seeing that. Good day though.
sukithedog
Posts: 494
Off Topic
Opinion:No Opinion
Price:0.72
View Thread (2)
RE: Suki
9 Feb '15
0.74p 30,000,000 £222,000 0.72p 0.75p Buy

nice , be more positive , this is a multi bagger
Wisheyedbortum
Posts: 483
Observation
Opinion:Buy
Price:0.70
View Thread (2)
Suki
9 Feb '15
Yes, great announcement this morning, but once again there's an "if" and no timescale, however this is still building nicely and as per usual I don't expect much movement in the sp, although how nice it would be to be proved wrong!
sukithedog
Posts: 494
Off Topic
Opinion:Strong Buy
Price:0.70
Just great
9 Feb '15
Avacta Group plc
("Avacta" or "the Group")

Partnership to develop Affimer assays for the market leading multiplex platform

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare announces that it has entered into a commercial partnership with ProtATonce, an approved Luminex partner, to develop and commercialise high performance multiplexed assays for the Luminex platform using Affimers.

ProtATonce is one of a number of exclusive Luminex partners selected to develop and commercialise multiplexed assays on the market leading Luminex xMAPTM platform which enables large numbers of biological tests to be conducted and analysed quickly using bead based assay kits. The bead based assay market is worth $270m and around half of these assays are run using Luminex assay kits. ProtATonce specializes in developing high quality assays with high degrees of multiplexing to support the pharmaceutical industry in drug discovery, mode of action analysis and drug repositioning.

The Luminex technology itself is powerful and capable of carrying out up to 500 tests in one experiment, but this high level of multiplexing is only possible if the antibodies that are used in the test kits are specific and show no cross reactivity between tests. However, the cross reactivity of antibodies practically limits the degree of multiplexing of the Luminex technology to around 50 tests.

Under the terms of the agreement Avacta will provide Affimers to ProtATonce who will develop Affimer based assays that take advantage of the engineered specificity of Affimers to unlock the high multiplexing potential of the Luminex platform. The aim is for ProtATonce to develop assay kits with market leading, disruptive levels of multiplexing and commercialise these through larger commercial partners. Avacta will be entitled to a 50% share of future revenues derived from the Affimer based Luminex test kits with an agreed minimum annual sales level.

Dr Alastair Smith, Group Chief Executive commented:
"The Luminex platform is the market leading bead based multiplexed assay platform and the potential of Affimers to overcome the problems of antibody cross reactivity which limit the overall performance of the technology is very exciting.

ProtATonce has an excellent reputation for developing high quality, highly multiplexed assays and they are an excellent partner for us to work with to establish Affimers in the Luminex assay market. Indeed, all multiplexed assay platforms are ultimately limited by the specificity of the affinity reagents and therefore proving Affimers on the Luminex platform will open up the wider multiplexed assay market.

I have no doubt that if we are successful in developing Luminex assays with market leading degrees of multiplexing then these products will become very attractive to a number of larger commercial partners in this market.&quo
Wisheyedbortum
Posts: 483
Observation
Opinion:Buy
Price:0.70
PP
8 Feb '15
I think that if Avacta had to rely on Optim 2 and Sensitest, I may well have abandon ship, or at least reduced my holding, a while ago, but the Affimers are a whole new ballgame. This is a serious product.
PtolomyPsycon
Posts: 8
Off Topic
Opinion:No Opinion
Price:0.71
AVCT Potential
2 Feb '15
Glad to see both Wisheyedbortum and Sukithedog still very much on board. The return of intelligent discourse and talk of profitability, maybe in 2017. I still see Avacta as an excellent medium to long term hold, hoping for greater things to come. Strictly tongue in cheek, in recent months I have smiled at the light-hearted barrow boy talk about the abandonment of Porsches which have run out of fuel. Is this Canary Wharf talk? Such wags, perhaps it brings light relief for those unfortunate enough to have £500K plus mortgages in Islington, a stone's throw away from squalor.





Sign up for Live Prices


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.